Premature Ejaculation Clinical Trial
Official title:
Identification Des Bases moléculaires de l'éjaculation prématurée Primaire
NCT number | NCT02109302 |
Other study ID # | C12-32 |
Secondary ID | 2012-A01055-38 |
Status | Not yet recruiting |
Phase | N/A |
First received | April 2, 2014 |
Last updated | April 7, 2014 |
The main objective of our study is to identify the first genetic etiology of primary Premature Ejaculation (PE). We will test and evaluate the existence of genetic determinism conferring susceptibility to a life-long syndrome (primary premature ejaculation) in some patients. To this end, we plan to establish a collection of biological samples and a database of patients with this extreme syndrome, which we will analyze by Genome Wide analysis. This will lead to improvements in the biological understanding, the "knowledge" of physicians of the disease, and should improve the patients' quality of life. Not all PE cases have the same physiopathology and treatment efficiency, which depend on the specific mechanism involved in the clinical context. Our work will make it possible to develop new therapeutic approaches suitable for a large proportion of individuals presenting PE. This integrative approach combining researchers, patients and ethics committees will facilitate profound reflection, promoting the creation of suitable structures capable of receiving patients for appropriate consultations. This unique study of PE should also favor industrial partnerships.
Status | Not yet recruiting |
Enrollment | 70 |
Est. completion date | |
Est. primary completion date | April 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. . Patients (index cases ) Prospective and retrospective cases - Man aged over 18 years - signing the informed consent - Presenting primary PE - have an affiliation to a social security system 2. . Related - Male or female over 18 years - be related to the index case - signing the informed consent - have an affiliation to a social security system Non Inclusion Criteria: 1. . Patients ( index case ) : - Be aged under 18 - have known genetic variations that predispose or can promote psychological disorders that can lead to PE ( eg: Kallman 's Syndrome , micropenis , testicular dysgenesis , Klinfelter syndrome, Leydig cell hypoplasia ) - have had psycho- social and psycho- traumatic factors in childhood - Inability to receive clear information on the protocol - Person deprived of liberty by judicial or administrative decision - Major Person subject of legal protection or unable to consent - Refusal to be informed of an abnormality detected after genetic testing - History of allergies to lidocaine or other anesthetic agent used during puncture or blood sample 2. . Related : - Age <18 years - Inability to receive clear information about the protocol . Unable to participate in the entire study. - No coverage by the social security system - Absence of signature of consent or refusal of the related party - Person deprived of liberty by judicial or administrative decision - Major Person subject of legal protection or unable to consent - Refusal to be informed of a genetic abnormality detected - History of allergies to lidocaine or other anesthetic agent used during puncture or blood sample |
Intervention Model: Single Group Assignment, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
France | Polyclinique de Blois | La Chaussée Saint Victor | |
France | Hôpital Saint Joseph | Marseille Cedex 08 | |
France | Hôpital Necker | Paris |
Lead Sponsor | Collaborator |
---|---|
Institut National de la Santé Et de la Recherche Médicale, France |
France,
Porto R, Giuliano F. [Premature ejaculation]. Prog Urol. 2013 Jul;23(9):647-56. doi: 10.1016/j.purol.2013.01.005. Epub 2013 Mar 1. Review. French. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects with genetic mutations of susceptibility to primary PE | We will perform WES (Whole Exome Sequencing) to identify shared defective genes in 20 patients. In case of genetic uniformity and of a genetically homogeneous recruitment, we hope to highlight such a gene in several individuals. As primary PE are very rare, this group should have defective genes at much higher frequencies than in the control population (NCBI, 1000 genome and housing-genome). This will allow us to identify genetic mutations of susceptibility to primary PE. | 4 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02232425 -
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
|
Phase 2 | |
Completed |
NCT01439984 -
Trial of PED-1 in Male Patients With Premature Ejaculation
|
Phase 3 | |
Completed |
NCT01203202 -
Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation
|
Phase 2 | |
Completed |
NCT01184105 -
A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
|
Phase 1 | |
Completed |
NCT03942367 -
Evaluation of the Safety and Effectiveness of the vPatch Device
|
N/A | |
Recruiting |
NCT06425211 -
Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
|
N/A | |
Completed |
NCT02939495 -
The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy
|
Phase 4 | |
Completed |
NCT02572037 -
Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research
|
||
Recruiting |
NCT02581826 -
Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
|
Phase 2 | |
Terminated |
NCT00983736 -
Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation
|
Phase 3 | |
Completed |
NCT00556478 -
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
|
Phase 2/Phase 3 | |
Completed |
NCT00549211 -
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
|
Phase 1 | |
Not yet recruiting |
NCT05556083 -
Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)
|
Phase 2 | |
Completed |
NCT03304808 -
Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0
|
N/A | |
Completed |
NCT00861484 -
Proof of Mechanism in ELT
|
Phase 1 | |
Completed |
NCT02984592 -
Effect of Exercise on Premature Ejaculation
|
N/A | |
Recruiting |
NCT02571101 -
A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation
|
Phase 2 | |
Completed |
NCT03174470 -
Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
|
N/A | |
Completed |
NCT02794454 -
A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health
|
N/A | |
Completed |
NCT02297152 -
A New Treatment for Premature Ejaculation?
|
N/A |